does tirzepatide cause liver damage Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty disease? Tirzepatide, a dual GIP/GLP-1 receptor

Because subcutaneous tissue thickness varies with body composition

This mechanism is fundamentally different from the indirect liver benefits seen with GLP-1 single agonists, which reduce liver fat primarily through weight loss and improved insulin sensitivity

Important safety screening topics Before any prescription therapy is considered, we review factors such as current medications, prior reactions, GI history, pancreatitis or gallbladder history, kidney issues, eye history in diabetes, mental health history, and whether there is any personal or family history of medullary thyroid carcinoma or MEN2depending on the medication being considered

GLP-1 slows intestinal motility vs